GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (NYSE:NVO) » Definitions » Book Value per Share

Novo Nordisk A/S (Novo Nordisk A/S) Book Value per Share : $3.23 (As of Mar. 2024)


View and export this data going back to 1981. Start your Free Trial

What is Novo Nordisk A/S Book Value per Share?

Novo Nordisk A/S's book value per share for the quarter that ended in Mar. 2024 was $3.23.

During the past 12 months, Novo Nordisk A/S's average Book Value Per Share Growth Rate was 24.80% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 21.10% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 17.10% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 11.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Novo Nordisk A/S was 21.10% per year. The lowest was -2.30% per year. And the median was 7.90% per year.

Novo Nordisk A/S's current price is $123.05. Its book value per share for the quarter that ended in Mar. 2024 was $3.23. Hence, today's PB Ratio of Novo Nordisk A/S is 38.07.

During the past 13 years, the highest P/B Ratio of Novo Nordisk A/S was 39.99. The lowest was 12.83. And the median was 18.39.

Warning Sign:

Novo Nordisk A/S stock PB Ratio (=38.37) is close to 10-year high of 39.99


Novo Nordisk A/S Book Value per Share Historical Data

The historical data trend for Novo Nordisk A/S's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk A/S Book Value per Share Chart

Novo Nordisk A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Book Value per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.79 2.20 2.33 2.64 3.50

Novo Nordisk A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.55 2.94 2.98 3.50 3.23

Competitive Comparison of Novo Nordisk A/S's Book Value per Share

For the Biotechnology subindustry, Novo Nordisk A/S's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novo Nordisk A/S's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novo Nordisk A/S's PB Ratio distribution charts can be found below:

* The bar in red indicates where Novo Nordisk A/S's PB Ratio falls into.



Novo Nordisk A/S Book Value per Share Calculation

Novo Nordisk A/S's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(15,591-0)/4,458
=3.50

Novo Nordisk A/S's Book Value Per Share for the quarter that ended in Mar. 2024 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(14,419-0)/4,462
=3.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Novo Nordisk A/S  (NYSE:NVO) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Novo Nordisk A/S Book Value per Share Related Terms

Thank you for viewing the detailed overview of Novo Nordisk A/S's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Novo Nordisk A/S (Novo Nordisk A/S) Business Description

Address
Novo Alle 1, Bagsvaerd, DNK, DK-2880
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.